Graft-versus-myeloma: Are durable responses a clinical reality following donor lymphocyte infusion? (multiple letters) [2]

Leukemia

Volumn 18, Issue 9, 2004, Pages 1541-1543

  Peggs, K ^a   Mackinnon, S ^a   Ayuk, F A ^b   Zander, A R ^b   Kroger N ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; DNA VACCINE; FLUDARABINE; MELPHALAN; THALIDOMIDE;

ADOPTIVE IMMUNOTHERAPY; CANCER SURVIVAL; CHIMERA; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DONOR; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; KAPLAN MEIER METHOD; LETTER; LYMPHOCYTE TRANSFUSION; MORBIDITY; MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT TANDEM REPEAT; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR RECURRENCE; VACCINATION; BLOOD DONOR; IMMUNOLOGY; LYMPHOCYTE; MULTIPLE MYELOMA; NOTE;

BLOOD DONORS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MULTIPLE MYELOMA;

EID: 19244366432     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403432     Document Type: Letter

References (0)